EXEL
EXELIXIS, INC.
Key Financials
Gross Profit
$191.3M
↑ 19.7%
Net Income
$782.6M
↑ 50.1%
Operating Income
$872.2M
↑ 44.3%
Revenue
$2.3B
↑ 7.0%
EPS (Diluted)
$2.78
↑ 58.0%
Shareholders' Equity
$2.2B
↓ 3.7%
Cash & Equivalents
$482.5M
↑ 122.0%
Total Liabilities
$683.1M
↓ 2.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 8/14/2026 | View on SEC |
| 4 | 8/12/2026 | View on SEC |
| SCHEDULE 13G/A | 8/12/2026 | View on SEC |
| 144 | 8/10/2026 | View on SEC |
| S-8 | 8/5/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 144 | 6/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EXEL |
| Company Name | EXELIXIS, INC. |
| CIK | 939767 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0101 |
| State of Incorporation | DE |
| Phone | 6508377000 |